<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953431</url>
  </required_header>
  <id_info>
    <org_study_id>16-061</org_study_id>
    <nct_id>NCT02953431</nct_id>
  </id_info>
  <brief_title>Increased Lung Volume as Controller Therapy for Asthma</brief_title>
  <official_title>Increased Lung Volume as Controller Therapy for Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early phase clinical trial to test the efficacy of elevating lung volume with&#xD;
      positive expiratory pressure (CPAP) as a controller therapy for asthma in patients with a BMI&#xD;
      ≥ 30 kg/m2.&#xD;
&#xD;
      There will be two phases to this trial.&#xD;
&#xD;
      Phase I:&#xD;
&#xD;
      In the first phase we will determine the optimal duration of CPAP that is effective as a&#xD;
      controller therapy in asthma. Up to 9 participants will complete this this phase.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      The 2nd phase will be a randomized double-blinded controlled trial of Sham CPAP versus CPAP&#xD;
      10 (using the duration of CPAP determined in phase I) as a controller therapy for asthma, and&#xD;
      also to determine the effect o airway reactivity in healthy people with a BMI 30 kg/m2 and&#xD;
      above. Twenty people with asthma and twenty controls will complete this phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of 10 versus 0 cmH2O CPAP on airways responsiveness to inhaled methacholine will&#xD;
      be studied using an adaptive &quot;3+3&quot; phase I/II study design.&#xD;
&#xD;
      Dose Titration Phase (phase I):&#xD;
&#xD;
      The efficacy of 8 hours of CPAP on airway responsiveness will be tested in three subjects.&#xD;
&#xD;
      Efficacy will be defined as a 25% improvement in the impedance response to methacholine in&#xD;
      all three subjects. If this occurs in all subjects, shorter durations of CPAP will be studied&#xD;
      (4 hours then one hour).&#xD;
&#xD;
      Conversely, if &quot;dose escalation&quot; is required, 3 nights, then 7 nights of CPAP will be&#xD;
      studied.&#xD;
&#xD;
      Randomized-controlled study phase (phase II):&#xD;
&#xD;
      Participants will be randomized to CPAP 10 or Sham 0. The duration of CPAP will be determined&#xD;
      in the dose titration phase. The effect on response to inhaled methacholine, lung function&#xD;
      and asthma control will be determined in patients with asthma and a BMI ≥ 30 kg/m2, and also&#xD;
      in healthy controls without asthma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in impedance of lung in response to methacholine measured by forced oscillation</measure>
    <time_frame>Through study completion, an average of one week</time_frame>
    <description>Average change in impedance in response to methacholine in participants assigned to Sham CPAP versus CPAP 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in spirometric lung function (FEV1 and FVC)</measure>
    <time_frame>Through study completion, an average of one week</time_frame>
    <description>Average change in lung function in response to methacholine in participants assigned to Sham CPAP versus CPAP 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in asthma control</measure>
    <time_frame>Through study completion, an average of one week</time_frame>
    <description>Average change in asthma control in response to methacholine in participants assigned to Sham CPAP versus CPAP 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sham CPAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to Sham CPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to CPAP 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP will be administered with a CPAP machine</description>
    <arm_group_label>CPAP 10</arm_group_label>
    <arm_group_label>Sham CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for people with asthma:&#xD;
&#xD;
          1. Physician diagnosis of asthma&#xD;
&#xD;
          2. PC20 to methacholine &lt; 16 mg/ml&#xD;
&#xD;
          3. IgE &lt; 100 IU/ml&#xD;
&#xD;
          4. Ages 18-65 years&#xD;
&#xD;
          5. BMI &gt;=30 kg/m2&#xD;
&#xD;
        Inclusion Criteria for controls:&#xD;
&#xD;
          1. No physician diagnosis of asthma&#xD;
&#xD;
          2. PC20 to methacholine &gt; 16 mg/ml&#xD;
&#xD;
          3. IgE &lt; 100 IU/ml&#xD;
&#xD;
          4. Ages 18-65 years&#xD;
&#xD;
          5. BMI &gt;=30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. FEV1 &lt; 60 % predicted&#xD;
&#xD;
          2. Other significant disease that in the opinion of the investigator would interfere with&#xD;
             study.&#xD;
&#xD;
          3. Inability to perform required testing.&#xD;
&#xD;
          4. Smoking within last 6 months.&#xD;
&#xD;
          5. ≥ 20 pack year smoking history&#xD;
&#xD;
          6. Inability to provide informed consent&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Known obstructive sleep apnea/ high likelihood of obstructive sleep apnea&#xD;
&#xD;
          9. Asthma exacerbation in the prior 6 weeks&#xD;
&#xD;
         10. Stoke or heart attack in the prior 3 months&#xD;
&#xD;
         11. Known aortic aneurysm&#xD;
&#xD;
         12. Renal failure&#xD;
&#xD;
         13. A known severe heart, vascular, liver, renal, or hematological disease&#xD;
&#xD;
         14. Active allergic rhinitis&#xD;
&#xD;
         15. Recent eye surgery (within the last month)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Dixon, BM BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Dixon, BM BCh</last_name>
    <phone>802 656 3525</phone>
    <email>anne.dixon@uvm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Johnson, MS, RDN</last_name>
    <phone>802-847-2160</phone>
    <email>olivia.johnson@uvmhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vermont Lung Center</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Johnson, MS, RDN</last_name>
      <phone>802-847-2160</phone>
      <email>olivia.johnson@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bates JH, Dixon AE. Potential role of the airway wall in the asthma of obesity. J Appl Physiol (1985). 2015 Jan 1;118(1):36-41. doi: 10.1152/japplphysiol.00684.2014. Epub 2014 Oct 23.</citation>
    <PMID>25342709</PMID>
  </results_reference>
  <results_reference>
    <citation>Chapman DG, Irvin CG, Kaminsky DA, Forgione PM, Bates JH, Dixon AE. Influence of distinct asthma phenotypes on lung function following weight loss in the obese. Respirology. 2014 Nov;19(8):1170-7. doi: 10.1111/resp.12368. Epub 2014 Aug 19.</citation>
    <PMID>25138203</PMID>
  </results_reference>
  <results_reference>
    <citation>Al-Alwan A, Bates JH, Chapman DG, Kaminsky DA, DeSarno MJ, Irvin CG, Dixon AE. The nonallergic asthma of obesity. A matter of distal lung compliance. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1494-502. doi: 10.1164/rccm.201401-0178OC.</citation>
    <PMID>24821412</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Anne Dixon</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in the archival literature, and this will include a complete description of experimental and analytical methods used. All original data will be stored and available to interested investigators with appropriate regulatory approvals in place</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

